Letters Outlining FDA’s Need for More Resources to Review Promising AD Therapies

ACT-AD submitted letters to the House and Senate subcommittees that handle FDA appropriations outlining FDA’s need for more resources to review promising AD therapies.
Read House Letter
Read Senate Letter